COVID-19
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
The COVID-19 pandemic that has upended life across the globe has also ignited a reawakening to the value of vaccines, and Hu believes the momentum will carry forward into the new year.
Slaoui will stay on as an adviser for one month. His resignation from the vaccine program was made at the request of the incoming Biden administration.
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
Publicly-traded companies that have been heavily involved in developing therapies and vaccines for COVID-19 have seen significant spikes in their stock prices over the past 10 months, including Germany’s BioNTech, which has surged 187% in one year.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
The advancing rollout of currently approved coronavirus disease 2019 (COVID-19) vaccines provides hope to many that existing lockdowns and social restrictions will soon be lifted, but experts suggest a “return to normal” likely won’t occur until herd immunity is achieved.
On Friday, the U.S. Food and Drug Administration (FDA) issued an official alert stating that it could trigger false negatives in COVID-19 tests.
Evidence continues to build for long-lasting immunity to COVID-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.
The new year began with a fairly low level of clinical trial news. Here’s a look.
PRESS RELEASES